The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 09, 2019
Filed:
Jun. 05, 2014
Applicant:
Acelrx Pharmaceuticals, Inc., Redwood City, CA (US);
Inventors:
Pamela Palmer, San Francisco, CA (US);
Thomas Schreck, Portola Valley, CA (US);
Stelios Tzannis, Petaluma, CA (US);
Lawrence Hamel, Pacific Grove, CA (US);
Andrew I. Poutiatine, Mill Valley, CA (US);
Assignee:
AcelRx Pharmaceuticals, Inc., Redwood City, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61J 7/00 (2006.01); A61J 7/04 (2006.01); A61K 31/4535 (2006.01); A61M 15/00 (2006.01); G07F 17/00 (2006.01); H01Q 1/22 (2006.01); G07C 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 9/20 (2013.01); A61J 7/0038 (2013.01); A61J 7/0053 (2013.01); A61J 7/0481 (2013.01); A61K 9/006 (2013.01); A61K 9/2009 (2013.01); A61K 9/2018 (2013.01); A61K 9/2031 (2013.01); A61K 9/2072 (2013.01); A61K 31/4535 (2013.01); A61M 15/00 (2013.01); A61M 15/008 (2014.02); A61M 15/0081 (2014.02); A61M 15/0083 (2014.02); G07F 17/0092 (2013.01); H01Q 1/2208 (2013.01); A61J 7/0418 (2015.05); A61J 7/0445 (2015.05); A61J 2200/30 (2013.01); A61M 2205/276 (2013.01); A61M 2205/3561 (2013.01); A61M 2205/3584 (2013.01); A61M 2205/3592 (2013.01); A61M 2205/52 (2013.01); A61M 2205/583 (2013.01); A61M 2205/609 (2013.01); A61M 2205/6054 (2013.01); A61M 2209/086 (2013.01); G07C 9/00031 (2013.01);
Abstract
Small-volume oral transmucosal dosage forms or NanoTabs® comprising a predetermined amount of a pharmaceutically active drug are provided. Exemplary applications include use of the NanoTabs® to administer a drug for the treatment of acute, post-operative or breakthrough pain.